The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global stem cell banking market reached a value of US$ 6.8 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 10.9 Billion by 2027, exhibiting a CAGR of 8.42% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Stem cell banking is one of the most promising as well as the fastest growing segment of the next-generation stem cell therapy. It is the process of extracting, freezing and storing stem cells for potential future use. Some of the sources through which stem cells are obtained include embryo, umbilical cord, cord blood, placenta and bone marrow. These cells are used for treating a number of different diseases including diabetes, thalassemia, leukemia, sickle cell anemia and cardiac diseases. Moreover, they are also employed for generating platelets, red blood cells and white blood cells. The potential of stem cells to regenerate has led to their applications in tissue engineering, gene therapy and regenerative medicines.
Global Stem Cell Banking Market Drivers:
IMARC Group provides an analysis of the key trends in each sub-segment of the global stem cell banking market, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on product type, service type, bank type, utilization and application.
Breakup by Product Type:
On the basis of product types, the market has been segmented as adult stem cells, human embryonic cells and IPS cells. Presently, adult stem cells account for the majority of the market share as they help in repairing damaged tissues via cell division. In addition to this, adult stem cells offer advantages like ease of harvesting, high acceptance in the human body and effectiveness in tissue generation.
Breakup by Service Type:
Based on service types, the market has been segmented as sample preservation and storage, sample analysis, sample processing, and sample collection and transportation.
Breakup by Bank Type:
Based on the bank type, the market has been segregated as private and public stem cell banks. Private stem cell banks currently dominate the market, holding the largest share.
Breakup by Utilization:
Based on the utilization, the market has been segregated as used and unused.
Breakup by Application:
On the basis of application, the market has been segmented as personalized banking applications, research applications and clinical applications.
On a geographical front, North America enjoys the leading position in the global stem cell banking market on account of advancements in medical infrastructure and availability of federal funding for stem cell research. Other regions include Europe, Asia Pacific, Middle East and Africa, and Latin America.
The market is fragmented in nature with the presence various international as well as regional players. Some of the leading players operating in the market are:
|Base Year of the Analysis||2021|
|Segment Coverage||Product Type, Service Type, Bank Type, Utilization, Application, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Companies Covered||CBR Systems Inc., China Cord Blood Corporation, Cordlife, Cordvida, Cryo-Cell International, Inc., Cryo-Save AG (A Group of Esperite), Cryoviva India, Lifecell, Smart Cells International Ltd and Viacord|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The global stem cell banking market was valued at US$ 6.8 Billion in 2021.
We expect the global stem cell banking market to exhibit a CAGR of 8.42% during 2022-2027.
The increasing consumer awareness towards numerous therapeutic benefits of stem cells for treating
several diseases, including diabetes, leukemia, cardiac ailments, etc., is currently driving the global stem
cell banking market.
The sudden outbreak of the COVID-19 pandemic has led to the increasing application of next-generation
stem cell therapy for managing severe symptoms of the coronavirus infection.
Based on the product type, the global stem cell banking market can be segmented into adult stem cells,
human embryonic cells, and IPS cells. Currently, adult stem cells hold the majority of the total market
Based on the service type, the global stem cell banking market has been divided into sample
preservation and storage, sample analysis, sample processing, and sample collection and transportation.
Among these, sample preservation and storage currently exhibits a clear dominance in the market.
Based on the bank type, the global stem cell banking market can be categorized into private and public.
Currently, private stem cell banks account for the majority of the global market share.
Based on the utilization, the global stem cell banking market has been segregated into used and unused,
where unused currently holds the largest market share.
Based on the application, the global stem cell banking market can be bifurcated into personalized
banking applications, research applications, and clinical applications. Among these, clinical applications
currently exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Europe, Asia Pacific, Middle East
and Africa, and Latin America, where North America currently dominates the global market.
Some of the major players in the global stem cell banking market include CBR Systems Inc., China Cord
Blood Corporation, Cordlife, Cordvida, Cryo-Cell International, Inc., Cryo-Save AG (A Group of Esperite),
Cryoviva India, Lifecell, Smart Cells International Ltd., Viacord, etc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at